seragy raises €12M to build quantitative biomarkers for brain diseases
What's the deal? seragyDealroom has a profile for this one. Try Dealroom →, a Hanover-based biomarker company formerly known as ProsperodesDealroom has a profile for this one. Try Dealroom →, has secured €12 million to advance its SeRAS platform and expand its laboratory and analytical capabilities. The early-stage round combines debt financing, equity capital, and public funding from Commerzbank, the Mittelständische Beteiligungsgesellschaft, and the State of Lower SaxonyDealroom has a profile for this one. Try Dealroom →.
What's the endgame? seragy targets proteopathies — diseases such as Alzheimer's, Parkinson's, and ALS that are marked by pathological protein aggregation. Its SeRAS technology (Seed Replication, Analysis and Subtyping) generates molecular fingerprints from patient samples to identify disease subtypes.
What's different? Conventional seed amplification assays mostly offer binary detection without molecular resolution. seragy says its fingerprints instead reveal quantitative biological changes, helping drugmakers build more targeted therapies from early discovery through clinical development.
What's the money for? The company will grow its team in Hanover, expand its lab capacity, and strengthen its presence in European and international markets. It also plans to deepen collaborations with pharmaceutical and biotechnology partners.
Separately, The Michael J. Fox FoundationDealroom has a profile for this one. Try Dealroom → is backing a quantitative SeRAS-based assay for Parkinson's disease.
In their words: "This financing provides the foundation for us to transform how pathological protein aggregation is measured and understood," said Dr. Thorsten Lührs, managing partner for strategy and innovation and co-founder of seragy.
The signal: At €12 million, the round sits in the top 10% of all early-stage VC deals in Germany by size. That scale signals investor appetite for precision diagnostics in neurodegeneration, a field where existing tools struggle to quantify the molecular patterns drug developers need.
Read more: pr.lakeoconeebreeze.net
Image credit: U.S. Army Combat Capabilities Development Command
